vs

Side-by-side financial comparison of AbbVie (ABBV) and Broadcom (AVGO). Click either name above to swap in a different company.

Broadcom is the larger business by last-quarter revenue ($18.0B vs $16.6B, roughly 1.1× AbbVie). Broadcom runs the higher net margin — 47.3% vs 10.9%, a 36.4% gap on every dollar of revenue. On growth, Broadcom posted the faster year-over-year revenue change (28.2% vs 10.0%). Broadcom produced more free cash flow last quarter ($7.5B vs $4.9B). Over the past eight quarters, Broadcom's revenue compounded faster (22.7% CAGR vs 16.2%).

AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. They have produced drugs to treat a wide range of medical issues.

Broadcom Inc. is an American multinational designer, developer, manufacturer, and global supplier of a wide range of semiconductor and infrastructure software products. Broadcom's product offerings serve the data center, networking, software, broadband, wireless, storage, and industrial markets. As of 2025—amid the AI boom—Broadcom is one of the largest companies globally, and could be considered part of the Big Tech group and the Magnificent Seven, replacing Tesla.

ABBV vs AVGO — Head-to-Head

Bigger by revenue
AVGO
AVGO
1.1× larger
AVGO
$18.0B
$16.6B
ABBV
Growing faster (revenue YoY)
AVGO
AVGO
+18.1% gap
AVGO
28.2%
10.0%
ABBV
Higher net margin
AVGO
AVGO
36.4% more per $
AVGO
47.3%
10.9%
ABBV
More free cash flow
AVGO
AVGO
$2.6B more FCF
AVGO
$7.5B
$4.9B
ABBV
Faster 2-yr revenue CAGR
AVGO
AVGO
Annualised
AVGO
22.7%
16.2%
ABBV

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ABBV
ABBV
AVGO
AVGO
Revenue
$16.6B
$18.0B
Net Profit
$1.8B
$8.5B
Gross Margin
72.6%
68.0%
Operating Margin
27.3%
41.7%
Net Margin
10.9%
47.3%
Revenue YoY
10.0%
28.2%
Net Profit YoY
8354.5%
97.0%
EPS (diluted)
$1.02
$1.75

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ABBV
ABBV
AVGO
AVGO
Q4 25
$16.6B
$18.0B
Q3 25
$15.8B
$16.0B
Q2 25
$15.4B
$15.0B
Q1 25
$13.3B
$14.9B
Q4 24
$15.1B
$14.1B
Q3 24
$14.5B
$13.1B
Q2 24
$14.5B
$12.5B
Q1 24
$12.3B
$12.0B
Net Profit
ABBV
ABBV
AVGO
AVGO
Q4 25
$1.8B
$8.5B
Q3 25
$186.0M
$4.1B
Q2 25
$938.0M
$5.0B
Q1 25
$1.3B
$5.5B
Q4 24
$-22.0M
$4.3B
Q3 24
$1.6B
$-1.9B
Q2 24
$1.4B
$2.1B
Q1 24
$1.4B
$1.3B
Gross Margin
ABBV
ABBV
AVGO
AVGO
Q4 25
72.6%
68.0%
Q3 25
66.4%
67.1%
Q2 25
71.8%
68.0%
Q1 25
70.0%
68.0%
Q4 24
70.9%
64.1%
Q3 24
70.9%
63.9%
Q2 24
70.9%
62.3%
Q1 24
66.7%
61.7%
Operating Margin
ABBV
ABBV
AVGO
AVGO
Q4 25
27.3%
41.7%
Q3 25
12.1%
36.9%
Q2 25
31.7%
38.8%
Q1 25
28.0%
42.0%
Q4 24
-9.9%
32.9%
Q3 24
26.5%
29.0%
Q2 24
27.6%
23.7%
Q1 24
22.7%
17.4%
Net Margin
ABBV
ABBV
AVGO
AVGO
Q4 25
10.9%
47.3%
Q3 25
1.2%
26.0%
Q2 25
6.1%
33.1%
Q1 25
9.6%
36.9%
Q4 24
-0.1%
30.8%
Q3 24
10.8%
-14.3%
Q2 24
9.5%
17.0%
Q1 24
11.1%
11.1%
EPS (diluted)
ABBV
ABBV
AVGO
AVGO
Q4 25
$1.02
$1.75
Q3 25
$0.10
$0.85
Q2 25
$0.52
$1.03
Q1 25
$0.72
$1.14
Q4 24
$-0.03
$-5.63
Q3 24
$0.88
$-0.40
Q2 24
$0.77
$4.42
Q1 24
$0.77
$2.84

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ABBV
ABBV
AVGO
AVGO
Cash + ST InvestmentsLiquidity on hand
$5.3B
$16.2B
Total DebtLower is stronger
$58.9B
$62.0B
Stockholders' EquityBook value
$-3.3B
$81.3B
Total Assets
$134.0B
$171.1B
Debt / EquityLower = less leverage
0.76×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ABBV
ABBV
AVGO
AVGO
Q4 25
$5.3B
$16.2B
Q3 25
$5.7B
$10.7B
Q2 25
$6.5B
$9.5B
Q1 25
$5.2B
$9.3B
Q4 24
$5.6B
$9.3B
Q3 24
$7.3B
$10.0B
Q2 24
$13.2B
$9.8B
Q1 24
$18.1B
$11.9B
Total Debt
ABBV
ABBV
AVGO
AVGO
Q4 25
$58.9B
$62.0B
Q3 25
$63.0B
$62.8B
Q2 25
$63.0B
$61.8B
Q1 25
$64.5B
$60.9B
Q4 24
$60.3B
$66.3B
Q3 24
$58.5B
$66.8B
Q2 24
$58.0B
$71.6B
Q1 24
$63.8B
$73.5B
Stockholders' Equity
ABBV
ABBV
AVGO
AVGO
Q4 25
$-3.3B
$81.3B
Q3 25
$-2.6B
$73.3B
Q2 25
$-183.0M
$69.6B
Q1 25
$1.4B
$69.8B
Q4 24
$3.3B
$67.7B
Q3 24
$6.0B
$65.7B
Q2 24
$6.8B
$70.0B
Q1 24
$8.0B
$70.3B
Total Assets
ABBV
ABBV
AVGO
AVGO
Q4 25
$134.0B
$171.1B
Q3 25
$133.9B
$165.6B
Q2 25
$137.2B
$164.6B
Q1 25
$136.2B
$165.4B
Q4 24
$135.2B
$165.6B
Q3 24
$143.4B
$168.0B
Q2 24
$141.9B
$175.2B
Q1 24
$148.9B
$177.9B
Debt / Equity
ABBV
ABBV
AVGO
AVGO
Q4 25
0.76×
Q3 25
0.86×
Q2 25
0.89×
Q1 25
45.44×
0.87×
Q4 24
18.15×
0.98×
Q3 24
9.70×
1.02×
Q2 24
8.56×
1.02×
Q1 24
7.97×
1.05×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ABBV
ABBV
AVGO
AVGO
Operating Cash FlowLast quarter
$5.2B
$7.7B
Free Cash FlowOCF − Capex
$4.9B
$7.5B
FCF MarginFCF / Revenue
29.4%
41.4%
Capex IntensityCapex / Revenue
2.0%
1.3%
Cash ConversionOCF / Net Profit
2.87×
0.90×
TTM Free Cash FlowTrailing 4 quarters
$17.8B
$26.9B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ABBV
ABBV
AVGO
AVGO
Q4 25
$5.2B
$7.7B
Q3 25
$7.0B
$7.2B
Q2 25
$5.2B
$6.6B
Q1 25
$1.6B
$6.1B
Q4 24
$7.0B
$5.6B
Q3 24
$5.4B
$5.0B
Q2 24
$2.3B
$4.6B
Q1 24
$4.0B
$4.8B
Free Cash Flow
ABBV
ABBV
AVGO
AVGO
Q4 25
$4.9B
$7.5B
Q3 25
$6.6B
$7.0B
Q2 25
$4.9B
$6.4B
Q1 25
$1.4B
$6.0B
Q4 24
$6.8B
$5.5B
Q3 24
$5.2B
$4.8B
Q2 24
$2.0B
$4.4B
Q1 24
$3.8B
$4.7B
FCF Margin
ABBV
ABBV
AVGO
AVGO
Q4 25
29.4%
41.4%
Q3 25
42.1%
44.0%
Q2 25
31.7%
42.7%
Q1 25
10.5%
40.3%
Q4 24
44.7%
39.0%
Q3 24
35.9%
36.7%
Q2 24
14.0%
35.6%
Q1 24
31.3%
39.2%
Capex Intensity
ABBV
ABBV
AVGO
AVGO
Q4 25
2.0%
1.3%
Q3 25
2.4%
0.9%
Q2 25
1.7%
1.0%
Q1 25
1.8%
0.7%
Q4 24
1.9%
0.9%
Q3 24
1.7%
1.3%
Q2 24
1.7%
1.1%
Q1 24
1.6%
1.0%
Cash Conversion
ABBV
ABBV
AVGO
AVGO
Q4 25
2.87×
0.90×
Q3 25
37.76×
1.73×
Q2 25
5.49×
1.32×
Q1 25
1.27×
1.11×
Q4 24
1.30×
Q3 24
3.49×
Q2 24
1.66×
2.16×
Q1 24
2.95×
3.63×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ABBV
ABBV

Segment breakdown not available.

AVGO
AVGO

Semiconductor Solutions$11.1B61%
Infrastructure Software$6.9B39%

Related Comparisons